A phase 1, randomized, double-blind, single-center, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of ascending single oral doses of XW10172 in healthy adult subjects
Phase of Trial: Phase I
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs XW-10172 (Primary)
- Indications Narcolepsy
- Focus Adverse reactions
- Sponsors XW labs
- 27 May 2019 Status changed from recruiting to completed.
- 06 Jun 2018 Planned End Date changed from 22 Jun 2018 to 2 Aug 2018.
- 06 Jun 2018 Status changed from not yet recruiting to recruiting.